MAPT and Alzheimer disease: To demonstrate this concept, we have performed simultaneous quantification of clinically-relevant markers of AD, β-amyloid and PHF-tau, in FFPE brain tissue sections, recording accumulation of both pathologic proteins in AD cohort brain sections and near absence of these targets in Control cohort specimens, in agreement with previous studies37.